Objective To evaluate the clinical efficacy of benserazide hydrochloride combined with pramipexole hydrochloride in treatment of Parkinson disease.Methods A total of 65 cases of Parkinson dis-ease from Yixing Hospital Affiliated to Jiangsu University during Dec .2011 and Dec.2013 were included in the study,and randomly divided into the combined group and the control group according to random number table method:the combined group was given benserazide hydrochloride(starting dose of 250 mg per day,max-imum,to add to the 750 mg, divided 3 to 4 times daily medication ) joint hydrochloric acid pramipexole ( starting dose 0.375 mg/d, dosage added by 0.75 mg/d once every week, the maximum daily dose was 1.5 mg,3 times a day).The control group received only benserazide hydrochloride,usage same as the the combined group.Motor function and Unified Parkinson Disease Rating Scale(UPDRS) motion part examina-tion(Part Ⅲ) score were observed.Results After 12 weeks of treatment,UPDRS score for the combined group was (18 ±5),better than before treatment(30 ±5) and the control group(21 ±6),the difference was statistically significant ( P <0.05 );motor function improvement was better than the control group ( P <0.05).Conclusion Benserazide hydrochloride combined with pramipexole in the treatment of Parkinson disease can significantly improve the motor function of the patients .%目的：探讨多巴丝肼联合盐酸普拉克索治疗帕金森病的临床疗效。方法选取2011年12月至2013年12月江苏大学附属宜兴医院收治的65例帕金森病患者为研究对象，将患者按照随机数字表法分为联合组（35例）与对照组（30例），联合组给予多巴丝肼联合盐酸普拉克索治疗（多巴丝肼起始剂量为每日250 mg，最大时可加至750 mg，每日分3～4次用药；盐酸普拉克索起始剂量为每日0.375 mg，每周加量1次，每次日剂量增加0.75 mg，每日最大的剂量为1.5 mg，每日3次）。对照组单独给予多巴丝肼治疗，用法参照联合组。观察两组患者治疗后运动功能情况，并进行统一帕金森病评分量表（ UPDRS）运动检查部分（ Part Ⅲ）评分。结果治疗12周后，联合组UPDRS 评分为（18±5）分，优于治疗前的（30±5）分和对照组的（21±6）分，差异有统计学意义（P＜0.05）；运动功能改善（10 m折返步行时间除外）优于对照组（P＜0.05）。结论多巴丝肼联合盐酸普拉克索治疗帕金森病能显著地改善患者的运动功能。
展开▼
